SmallCaps
ASX:4DXHealth Care Equipment & ServicesHealth Care Technology

4DMedical Ltd

$3.840
+$0.130 (+3.50%)
Day Range
$3.650 – $3.910
52 Week Range
$0.230 – $7.550
Volume
1.94M
Avg Volume (10D)
5.71M
Market Cap
$2.29B
Price Chart
Market Statistics
Open$3.660
Previous Close$3.710
Day High$3.910
Day Low$3.650
52 Week High$7.550
52 Week Low$0.230
Valuation
Market Cap2.29B
Shares Outstanding595.36M
Trading Activity
Volume1.94M
Value Traded7.40M
Bid$3.830 × 9,777
Ask$3.850 × 6,831
Performance
1 Day-1.06%
5 Day-7.23%
13 Week-1.85%
52 Week1,303.77%
YTD-5.34%
Technical Indicators
RSI (14)50.77
50-Day SMA$4.294
200-Day SMA$3.287
Latest News
Pulmonary imaging takes a leap as UC San Diego Health adopts 4DMedical CT:VQ
Technology

Pulmonary imaging takes a leap as UC San Diego Health adopts 4DMedical CT:VQ

4D Medical (ASX: 4DX) inks UC San Diego Health as its 4th US centre to use CT:VQ, with launch pricing ahead of broader commercial rollout.

4DMedical Secures CT:VQ Imaging Commitment Through Expanded Philips Distribution Deal
Technology

4DMedical Secures CT:VQ Imaging Commitment Through Expanded Philips Distribution Deal

4DMedical (ASX: 4DX) has secured a minimum US$10 million (A$15m) order commitment for its FDA-approved CT:VQ imaging solution under an expanded distribution agreement with multinational giant Philips.

4DMedical Extends Imaging Technology into Public Hospitals and National Screening Network
Technology

4DMedical Extends Imaging Technology into Public Hospitals and National Screening Network

4DMedical (ASX: 4DX) has secured three significant agreements to expand the reach of its lung health imaging technology. In Australia, 4DMedical has locked in a multi-year deal with Spectrum Medical Imaging to support the National Lung Cancer Screening Program. The company will also launch a Brazilian lung screening program with a leading pharmaceutical partner, while […]

4DMedical Secures US Medicare Reimbursement Approval for CT:VQ Imaging Software
Technology

4DMedical Secures US Medicare Reimbursement Approval for CT:VQ Imaging Software

4DMedical (ASX: 4DX) has received reimbursement approval from the US Centers for Medicare & Medicaid Services (CMS) for its CT:VQ lung imaging platform. The decision follows Food and Drug Administration (FDA) clearance granted last week, aligning regulatory authorisation with a defined payment structure. Together, the approvals clear the path for commercial rollout of the software […]